Moreover, a previous study found that PD-1 inhibitors are less effective in treating NSCLC patients with EGFR mutations, and low levels of both programmed death-ligand 1 (PD-L1) and CD8+tumor infiltrating lymphocytes in the TME might be the basis of this adverse clinical response 18. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.